OGEN - Oragenics inks material transfer agreement for COVID-19 vaccine adjuvants

Oragenics ([[OGEN]] +38.5%) announces that it has entered into a material transfer agreement with Biodextris for the use of three intranasal mucosal adjuvants in the company’s Terra CoV-2 vaccine against COVID-19.The initial agreement is for the three intranasal adjuvants to be used in combination with the Oragenics’ antigen vaccine candidate as part of the preclinical immunological evaluation of Terra CoV-2, for the prevention of COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity.The company had entered into a material transfer agreement with Adjuvance Technologies for use of the adjuvant TQL1055 in Oragenics’ Terra CoV-2 vaccine against COVID-19, in January.

For further details see:

Oragenics inks material transfer agreement for COVID-19 vaccine adjuvants